Indian Council of Medical Research, New Delhi, 110029, India.
Department of Anthropology, University of Delhi, Delhi, 110007, India.
BMC Med Genomics. 2021 Feb 27;14(1):59. doi: 10.1186/s12920-021-00895-1.
Hypertension is a complex disorder affected by gene-environment interactions. Methylenetetrahydrofolate reductase (MTHFR) gene is one of the genes in One Carbon Metabolic (OCM) pathway that affects both blood pressure and epigenetic phenomenon. MTHFR C677T gene polymorphism leads to reduced methylation capacity via increased homocysteine concentrations. Global DNA methylation (5mC%) also gets affected in conditions such as hypertension. However, no study is found to understand hypertension in terms of both genetics and epigenetics. The present study aims to understand the relation between methylation, MTHFR C677T gene polymorphism and hypertension. It also tries to understand relation (if any) between methylation and anti-hypertensive drugs.
This is a cross-sectional study where data were collected from a total of 1634 individuals of either sex in age group 35-65 years. Hypertensives (SBP ≥ 140 mm Hg and DBP ≥ 90 mm Hg) (on treatment/not on treatment) and absolute controls were 236 (cases) and 307 (controls), respectively. All the samples were subjected to MTHFR C677T gene polymorphism screening (PCR-RFLP) and global DNA methylation assay (ELISA based colorimetric assay). Results of both the analyses were obtained on 218 cases, 263 controls.
Median 5mC% was relatively lower among cases (p > 0.05) compared to controls, despite controlling for confounders (age, sex, smoking, alcohol, diet) (r-0.92, p-0.08). Cases not on medication had significantly reduced 5mC% compared to controls (p < 0.05), despite adjusting for confounders (r-0.857, p-0.01). Among cases (irrespective of treatment), there was a significant variation in 5mC% across the three genotypes i.e. CC, CT and TT, with no such variation among controls. Cases (not on medication) with TT genotype had significantly lower methylation levels compared to the TT genotype controls and cases (on medication) (p < 0.01).
Global DNA hypomethylation seems to be associated with hypertension and antihypertensive drugs seem to improve methylation. Hypertensive individuals with TT genotype but not on medication are more likely to be prone to global DNA hypomethylation. Important precursors in OCM pathway include micronutrients such as vitamin B-12, B-9 and B-6; their nutritional interventions (either dietary or supplement) may serve as strategies to prevent hypertension at population level. However, more epidemiological-longitudinal studies are needed for further validation.
高血压是一种受基因-环境相互作用影响的复杂疾病。亚甲基四氢叶酸还原酶(MTHFR)基因是影响血压和表观遗传现象的一碳代谢(OCM)途径中的基因之一。MTHFR C677T 基因突变导致同型半胱氨酸浓度升高,甲基化能力降低。在高血压等情况下,全球 DNA 甲基化(5mC%)也会受到影响。然而,目前还没有研究从遗传学和表观遗传学两个方面来理解高血压。本研究旨在了解甲基化、MTHFR C677T 基因突变与高血压之间的关系。它还试图了解甲基化与抗高血压药物之间的关系(如果有的话)。
这是一项横断面研究,共收集了年龄在 35-65 岁的 1634 名男性和女性的资料。高血压患者(收缩压≥140mmHg 和舒张压≥90mmHg)(治疗/未治疗)和绝对对照组分别为 236 例(病例)和 307 例(对照组)。所有样本均进行 MTHFR C677T 基因突变筛查(PCR-RFLP)和全球 DNA 甲基化测定(ELISA 比色法)。对 218 例病例和 263 例对照进行了两项分析的结果。
与对照组相比,病例组的中位 5mC%相对较低(p>0.05),但在控制混杂因素(年龄、性别、吸烟、饮酒、饮食)后(r=0.92,p=0.08)。与对照组相比,未服用药物的病例组 5mC%显著降低(p<0.05),尽管在调整混杂因素后(r=0.857,p=0.01)。在病例组中(无论治疗与否),三种基因型(CC、CT 和 TT)之间的 5mC%存在显著差异,而对照组中则没有这种差异。与 TT 基因型的对照组和病例组(服用药物)相比,不服用药物的 TT 基因型病例组的甲基化水平明显较低(p<0.01)。
全基因组低甲基化似乎与高血压有关,而抗高血压药物似乎能改善甲基化。未服用药物的 TT 基因型高血压患者更有可能出现全基因组低甲基化。OCM 途径中的重要前体包括维生素 B-12、B-9 和 B-6 等微量营养素;它们的营养干预(饮食或补充)可能是预防人群高血压的策略。然而,还需要更多的流行病学-纵向研究来进一步验证。